Clinical Trials
Sep 04, 2026 · 1 min read · 85,876 views
Updated: Roivant reports Phase 2b lupus failure for an FcRn drug
A
Aiden Brooks
Editorial · Sep 04, 2026
One of Roivant's leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did not improve symptoms by a
← Previous
Pacing the Journey: A Framework to Commercial Readiness
Next →
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
